We’re thrilled to announce that MOLCURE has entered into a multi-year strategic research agreement with Boehringer Ingelheim! Together, we’ll discover innovative antibody therapeutics across multiple targets using our AI-driven platform.
https://t.co/uC6jiar4ka
On December 7 at 12:50 PM JST, CEO/CSO Satoshi Tamaki will give a presentation and join a panel at Healthtech Summit 2026 (@HealthtechSum) in Tokyo . Attend in person or online.
Link in thread.
On Nov 19, our CEO/CSO Satoshi Tamaki will pitch at the AI:360 Summit, the flagship global event of Extreme Tech Challenge (@ExTechChallenge; XTC), in Palo Alto, CA! Link in thread.
On Oct 13 at 2:00 PM JST, our CEO/CSO Satoshi Tamaki will give a case presentation at the kick-off event for the third-phase project of the National Cancer Center Tsuruoka Collaborative Research Center in Tsuruoka Science Park.
Link in thread.
Final day of BioJapan 2026! At 10:20 AM JST, our CEO/CSO Satoshi Tamaki will join the panel "From Discovery to Impact: Shaping the Future of Innovation," co-hosted by iPark Institute and Johnson & Johnson, at Presentation Stage B. We're also at Booth A-06 all day!
Day 2 of BioJapan 2026! Today at 11:00 AM JST, our CEO/CSO Satoshi Tamaki will give a pitch on the stage at the Cabinet Office Pavilion (Booth A-06). Come learn how we are advancing AI-driven antibody discovery!
BioJapan 2026 opens today! Visit MOLCURE at the Cabinet Office Pavilion, Booth A-06. At 1:30 PM JST, our Chief Innovation Officer (CIO) Ryu Ogawa will speak at the JBA seminar "New Modalities × AI-Driven Drug Discovery: Current Landscape and Future." Please stop by!